This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Masimo's (MASI) W1 Watch Gains FDA Nod for SafetyNet Connectivity
by Zacks Equity Research
The latest FDA clearance of Masimo's (MASI) W1 medical watch is likely to provide a continuous and accurate view of patients' health data.
Labcorp (LH) Gains From New Collaborations Amid FX Issues
by Zacks Equity Research
Labcorp's (LH) Biopharma Laboratory Services business is benefiting from collaborations with leading pharmaceutical and biotechnology companies.
Quest Diagnostics (DGX) Gains From Innovation, Customer Wins
by Zacks Equity Research
A key driver in Brain Health growth is Quest Diagnostics' (DGX) Alzheimer's disease portfolio, featuring the AD-Detect blood testing services and the CSF Tests for diagnosing and monitoring.
Thermo Fisher's (TMO) CDx Gets FDA's Nod for Synovial Sarcoma
by Zacks Equity Research
Thermo Fisher's (TMO) SeCore HLA Typing Kit gets FDA's 510(k) clearance for use as CDx with a TCR Therapy for synovial sarcoma
New Strong Buy Stocks for August 9th
by Zacks Equity Research
LSPD, CART, MASI, STRL and DKL have been added to the Zacks Rank #1 (Strong Buy) List on August 9, 2024.
What Makes Masimo (MASI) a New Buy Stock
by Zacks Equity Research
Masimo (MASI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Masimo (MASI) Q2 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
Strength in Healthcare revenues drive Masimo's (MASI) second-quarter results.
Compared to Estimates, Masimo (MASI) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Masimo (MASI) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Masimo (MASI) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 11.69% and 0.24%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of 0% and 8.24%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
West Pharmaceutical (WST) Misses on Q2 Earnings, Lowers '24 View
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter results reflect a declining demand for products across its segments amid elevated customer destocking.
Thermo Fisher Scientific (TMO) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 4.68% and 0.29%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Intuitive Surgical (ISRG) Q2 Earnings Beat, Procedures Robust
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results reflect a healthy demand for procedures. Higher pricing boosts procedure sales. An improvement in margins buoys well.
Reasons to Add Masimo (MASI) Stock to Your Portfolio Now
by Zacks Equity Research
Masimo's (MASI) R&D activities raise optimism about the stock.
Masimo (MASI) Sues Politan for Misstatements, Delays Annual Meet
by Zacks Equity Research
Masimo (MASI) sues Politan to correct material misstatements in an ongoing proxy battle, rescheduling its annual meeting. Politan denies allegations and vows to prevent any further delay, criticizing Masimo's tactics.
Masimo (MASI) Gets Non-Binding Offer for Consumer Business
by Zacks Equity Research
Masimo (MASI) gets an acquisition offer for its consumer business from an undisclosed entity. The deal is likely to close later in 2024.
Masimo (MASI) Preliminary Q2 Results Aided by Healthcare Unit
by Zacks Equity Research
Masimo's (MASI) second-quarter 2024 results are likely to reflect the strength in the Healthcare business.
Masimo (MASI) Fights Politan in a Bid to Retain CEO on Board
by Zacks Equity Research
Will Masimo (MASI) lose its CEO in its fight against activist investor Politan Capital Management? The company's management and employees want Joe Kiani to continue as the CEO.
Masimo's (MASI) WI Sport Wearable Gets a New Powerful Feature
by Zacks Equity Research
Masimo (MASI) announces Sleep Halo, a new feature for its Masimo W1 Sport advanced health tracking wearable.
Masimo (MASI), Cleveland Clinic Unite to Enhance Patient Care
by Zacks Equity Research
Masimo (MASI) collaborates with Cleveland Clinic to boost patient care by combining its Hospital Automation platform with the latter's central patient monitoring platforms.
3 Medical Instruments Picks to Navigate Industry Challenges
by Urmimala Biswas
Deteriorating geopolitical situation and supply bottlenecks mar the prospects of the Zacks Medical Instruments industry. Yet, HOLX, MASI and VCYT are worth buying based on strategic developments and fundamentals.
5 Sector ETFs & Stocks to Benefit From May Inflation Report
by Sanghamitra Saha
US annual inflation rate slowed to 3.3% in May 2024, the lowest in three months, compared to 3.4% in April and forecasts of 3.4%.
Reasons to Add Masimo (MASI) Stock to Your Portfolio Now
by Zacks Equity Research
Masimo's (MASI) R&D activities raise optimism about the stock.
Best Momentum Stocks to Buy for June 5th
by Zacks Equity Research
BAC, GPS and MASI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 5, 2024.
Buy 5 Medical Instruments Stocks to Enhance Your Portfolio
by Nalak Das
We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These stocks are: ALC, RXST, HOLX, VCYT, MASI.